Details:
Under the agreement, Fareva will fill & finish manufacturing of CureVac´s COVID-19 vaccine candidate, CVnCoV, a COVID-19 vaccine candidate developed by CureVac, in France.
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CureVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 08, 2020